Effect of hydroalcoholic root extract of berberis vulgaris in patients with Type2 Diabetes.

The randomized.placebo controlled clinical trial of Berberis vulgaris hydroalcoholic root extract capsules on glycaemic and lipid parameters in type 2 diabetes mellitus patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201504264610N3

Enrollment

Registered

2015-05-03

Start date

2014-03-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Forty-two Patients in addition to previous medications, Berberis vulgaris root extract Capsule 500 mg twice per day, every twelve hours for six weeks. Intervention 2: Forty-two Patient

Treatment - Drugs

Placebo

Forty-two Patients in addition to previous medications, Berberis vulgaris root extract Capsule 500 mg twice per day, every twelve hours for six weeks.

Forty-two Patients in addition to previous medications, placebo Capsule 500 mg twice per day, every twelve hours for six weeks

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 20-65 years; HbA1C <8.5; Fasting Blood Sugar <200; diagnosis of Diabetes less than 1 years; Only use oral blood glucose lowering drugs. Exclusion critria: triglyceride More Than 500 ;pregnancy; Consumers of anticoagulants drugs (except Aspirin); chronic liver disease except fatty liver disease; Renal Failure; Heart failure; Hemorrhagic strokes; hypothyroidism and hyperthyroidism

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Timepoint: baseline, after six weeks. Method of measurement: Blood samples from patients, mg/dl.;2hpp (2 hour post prandial) blood glucose. Timepoint: baseline , after six weeks. Method of measurement: Blood samples from patients, mg/dl.;Fructosamine. Timepoint: baseline, after six weeks. Method of measurement: Blood samples from patients ,umol.	—

Secondary

Measure	Time frame
Lipid profile. Timepoint: baseline, after six weeks. Method of measurement: Blood samples from patients, mg /dl.;Blood pressure. Timepoint: baseline , after six weeks. Method of measurement: Manometer, mmHg.;Body Mass Index. Timepoint: baseline, after six weeks. Method of measurement: calculated as weight (kg)/height (m2).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Foroogh Namjooyan

Ahvaz Jundishapur University of Medical Sciences

namjoyan@yahoo.com+98 61 3373 8381

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026